- Exchange: Frankfurt
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharma
Nektar Therapeutics+ Add to Watchlist
ITH:GR10.801 EUR 0.269 2.43%
As of 15:11:14 ET on 04/17/2015.
Company Profile for Nektar Therapeutics (ITH)
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.
Key Executives for Nektar Therapeutics (ITH)
|Howard W RobinPresident/CEO||John L NicholsonSenior VP/CFO|
|Stephen K DobersteinSenior VP/Chief Scientific Ofcr||Gil M LabrucherieSenior VP/Secy/Gen Counsel|
|Ivan P GergelSenior VP:Drug Dev/Chief Medical Ofcr||Jillian B ThomsenSenior VP:Finance|
|Maninder HoraSenior VP:Pharmaceutical Dev||Jennifer RuddockVP:Investor Relations|